{"DataElement":{"publicId":"12943983","version":"1","preferredName":"Targeted Prostate Biopsy NCCN Prostate Cancer Risk Stratification PSMA-targeting Agent-Technetium Tc99m EC0652 PET Category","preferredDefinition":"The NCCN prostate cancer risk stratification group using targeted prostate biopsy as determined by PSMA-targeted agent-Technetium Tc99m EC0652 PET scan.","longName":"TGTBX_NCCN_TC99M_CAT","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"12940047","version":"1","preferredName":"Targeted Prostate Biopsy National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease PSMA-targeting Agent-Technetium Tc99m EC0652 PET","preferredDefinition":"A method of image-guided needle biopsy which merges previously taken MRI images of suspected cancer with real-time ultrasound prostate tissue so that samples are preferentially taken from areas of interest or suspicion._A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy.:A radioconjugate composed of 2-[3-(1, 3-dicarboxy propyl)-ureido] pentanedioic acid (DUPA), a prostate-specific membrane antigen (PSMA)-targeting ligand, linked to the radioisotope technetium Tc 99m (Tc99m), that can potentially be used as a radioimaging agent for PSMA-overexpressing tumor cells. Upon administration, the PSMA-targeting moiety of EC0652 targets and binds to PSMA-expressing tumors. Upon uptake and single-photon emission computed tomography (SPECT) imaging, PSMA-expressing tumors can be visualized and identified. In turn, PSMA-overexpression can be used to evaluate both the efficacy of and response to certain PSMA-targeting cytotoxic agents. PSMA, a tumor-associated antigen (TAA), is overexpressed by most prostate cancers._A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","longName":"12940043v1.00:12940033v1.00","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"12940043","version":"1","preferredName":"Targeted Prostate Biopsy National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease","preferredDefinition":"A method of image-guided needle biopsy which merges previously taken MRI images of suspected cancer with real-time ultrasound prostate tissue so that samples are preferentially taken from areas of interest or suspicion._A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy.","longName":"C192889:C181084","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Targeted Prostate Biopsy","conceptCode":"C192889","definition":"A method of image-guided needle biopsy which merges previously taken MRI images of suspected cancer with real-time ultrasound prostate tissue so that samples are preferentially taken from areas of interest or suspicion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease","conceptCode":"C181084","definition":"A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CFAA4E-99A5-5EA9-E053-731AD00AEF2E","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"12940033","version":"1","preferredName":"PSMA-targeting Agent-Technetium Tc99m EC0652 Positron Emission Tomography","preferredDefinition":"A radioconjugate composed of 2-[3-(1, 3-dicarboxy propyl)-ureido] pentanedioic acid (DUPA), a prostate-specific membrane antigen (PSMA)-targeting ligand, linked to the radioisotope technetium Tc 99m (Tc99m), that can potentially be used as a radioimaging agent for PSMA-overexpressing tumor cells. Upon administration, the PSMA-targeting moiety of EC0652 targets and binds to PSMA-expressing tumors. Upon uptake and single-photon emission computed tomography (SPECT) imaging, PSMA-expressing tumors can be visualized and identified. In turn, PSMA-overexpression can be used to evaluate both the efficacy of and response to certain PSMA-targeting cytotoxic agents. PSMA, a tumor-associated antigen (TAA), is overexpressed by most prostate cancers._A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","longName":"C136776:C17007","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"PSMA-targeting Agent-Technetium Tc99m EC0652","conceptCode":"C136776","definition":"A radioconjugate composed of 2-[3-(1, 3-dicarboxy propyl)-ureido] pentanedioic acid (DUPA), a prostate-specific membrane antigen (PSMA)-targeting ligand, linked to the radioisotope technetium Tc 99m (Tc99m), that can potentially be used as a radioimaging agent for PSMA-overexpressing tumor cells. Upon administration, the PSMA-targeting moiety of EC0652 targets and binds to PSMA-expressing tumors. Upon uptake and single-photon emission computed tomography (SPECT) imaging, PSMA-expressing tumors can be visualized and identified. In turn, PSMA-overexpression can be used to evaluate both the efficacy of and response to certain PSMA-targeting cytotoxic agents. PSMA, a tumor-associated antigen (TAA), is overexpressed by most prostate cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Positron Emission Tomography","conceptCode":"C17007","definition":"A technique for measuring the gamma radiation produced by collisions of electrons and positrons (anti-electrons) within living tissue. In positron emission tomography (PET), a subject is given a dose of a positron-emitting radionuclide attached to a metabolically active substance (for example, 2-fluoro-2-deoxy-D-glucose (FDG), which is similar to a naturally occurring sugar, glucose, with the addition of a radioactive fluorine atom). When living tissue containing the positron emitter is bombarded by electrons, gamma radiation produced by collisions of electrons and positrons is detected by a scanner, revealing in fine detail the tissue location of the metabolically-active substance administered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CFA652-0FAC-5E24-E053-731AD00A2244","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435021","version":"1","preferredName":"Diagnostic or Prognostic Factor","preferredDefinition":"Top level term which includes Biological Markers, Risk Factors, and Prognostic Factors.","longName":"C20047","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741C99A-9B70-231B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5CFAE92-7B01-5F4E-E053-731AD00AACA6","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":"2023.3.6 Shortened LN (PET) due to import issues. ak 2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"12939854","version":"1","preferredName":"National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease Category","preferredDefinition":"A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy._A grouping of items based on some commonality or by user defined characteristics.","longName":"PC_RSK_CAT","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"45","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Very Low Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940069","version":"1","preferredName":"NCCN Prostate Cancer Very Low Risk Group","longName":"12940069v1.00","preferredDefinition":"A prostate cancer risk group characterized by: clinical stage T1c, biopsy Gleason score of 6 or less, and PSA level less than 10.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Very Low Risk Group","conceptCode":"C192873","definition":"A prostate cancer risk group characterized by: clinical stage T1c, biopsy Gleason score of 6 or less, and PSA level less than 10.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-116C-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-117C-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Low Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940070","version":"1","preferredName":"NCCN Prostate Cancer Low Risk Group","longName":"12940070v1.00","preferredDefinition":"A prostate cancer risk group characterized by: clinical stage T1-T2a, biopsy Gleason score of 6 or less, and PSA level less than 10 ng/mL.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Low Risk Group","conceptCode":"C192874","definition":"A prostate cancer risk group characterized by: clinical stage T1-T2a, biopsy Gleason score of 6 or less, and PSA level less than 10 ng/mL.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-116D-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-117D-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Favorable-Intermediate Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940071","version":"1","preferredName":"NCCN Prostate Cancer Favorable-Intermediate Risk Group","longName":"12940071v1.00","preferredDefinition":"A prostate cancer risk group characterized by: Gleason score of 3 + 4 or less, positive biopsy cores less than 50%, and at most 1 determinant of intermediate risk.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Favorable-Intermediate Risk Group","conceptCode":"C192876","definition":"A prostate cancer risk group characterized by: Gleason score of 3 + 4 or less, positive biopsy cores less than 50%, and at most 1 determinant of intermediate risk.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-116E-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-117E-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Unfavorable-Intermediate Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940072","version":"1","preferredName":"NCCN Prostate Cancer Unfavorable-Intermediate Risk Group","longName":"12940072v1.00","preferredDefinition":"A prostate cancer risk group characterized by: primary Gleason pattern 4, positive biopsy cores greater than or equal to 50%, or multiple determinants of intermediate risk.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Unfavorable-Intermediate Risk Group","conceptCode":"C192877","definition":"A prostate cancer risk group characterized by: primary Gleason pattern 4, positive biopsy cores greater than or equal to 50%, or multiple determinants of intermediate risk.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-116F-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-117F-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"High Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940073","version":"1","preferredName":"NCCN Prostate Cancer High Risk Group","longName":"12940073v1.00","preferredDefinition":"A prostate cancer risk group characterized by: clinical stage T3a, or biopsy Gleason score 8-10, or PSA level greater than 20 ng/mL.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer High Risk Group","conceptCode":"C192878","definition":"A prostate cancer risk group characterized by: clinical stage T3a, or biopsy Gleason score 8-10, or PSA level greater than 20 ng/mL.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-1170-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-1180-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"},{"value":"Very High Risk","valueDescription":null,"ValueMeaning":{"publicId":"12940074","version":"1","preferredName":"NCCN Prostate Cancer Very High Risk Group","longName":"12940074v1.00","preferredDefinition":"A prostate cancer risk group characterized by clinical stage T3b or T4, biopsy Gleason score 9 or 10, or N1, N2, or N3 with any stage T, or M1 with any stage T.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"NCCN Prostate Cancer Very High Risk Group","conceptCode":"C192879","definition":"A prostate cancer risk group characterized by clinical stage T3b or T4, biopsy Gleason score 9 or 10, or N1, N2, or N3 with any stage T, or M1 with any stage T.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D03394-1171-7618-E053-731AD00A59B8","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F5D03394-1181-7618-E053-731AD00A59B8","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"12939853","version":"1","preferredName":"National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease Category","preferredDefinition":"A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy._A grouping of items based on some commonality or by user defined characteristics.","longName":"12939853v1.00","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"National Comprehensive Cancer Network Prostate Cancer Risk Stratification for Clinically Localized Disease","conceptCode":"C181084","definition":"A prostate cancer risk stratification system developed by the National Comprehensive Cancer Network that utilizes clinical tumor stage, Gleason grade, serum prostate specific antigen level, and other factors, including the percentage of positive biopsy cores, to select appropriate treatment options and predict the probability of biochemical recurrence after definitive local therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5C9F7DC-ACE6-6510-E053-731AD00A15B5","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"GDEEN","dateModified":"2023-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5C9F7DC-ACED-6510-E053-731AD00A15B5","latestVersionIndicator":"Yes","beginDate":"2023-02-28","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-02-28","modifiedBy":"KUMMEROA","dateModified":"2023-03-03","changeDescription":null,"administrativeNotes":"2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Tc99m (Risk Stratification Using Targeted Biopsy)","type":"Preferred Question Text","description":"Tc99m (Risk Stratification Using Targeted Biopsy)","url":null,"context":"CCR"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5D11B44-0E25-0AD0-E053-731AD00A29A8","latestVersionIndicator":"Yes","beginDate":"2023-03-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-03-01","modifiedBy":"KUMMEROA","dateModified":"2023-03-06","changeDescription":null,"administrativeNotes":"2023.3.6 Shortened (PET) LN due to Import issues. ak 2023.3.3 Released per CCR review. ak","unresolvedIssues":null,"deletedIndicator":"No"}}